^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersBIOMARKER:
ALK mutation
i
Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4d
JK06.1.01: A Phase 1/2, Multicenter, Open Label, Dose Escalation and Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unresectable Locally Advanced or Metastatic Cancer (2024-512421-92-00)
P1/2, N=305, Recruiting, Salubris Biotherapeutics Inc. | N=210 --> 305
Enrollment change
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
HER-2 positive • EGFR mutation • HR positive • HER-2 negative • ALK mutation • ROS1 fusion • ESR1 mutation • HER-2 negative + HR negative • HER-2 negative + HR positive + ESR1 mutation
9d
NCI-2015-01097: A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors (clinicaltrials.gov)
P2, N=122, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027
Trial completion date
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 expression • ALK mutation
|
Lynparza (olaparib) • Recentin (cediranib)
10d
Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer (clinicaltrials.gov)
P2/3, N=33, Completed, Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting --> Completed | N=80 --> 33 | Trial primary completion date: Mar 2022 --> Oct 2025
Trial completion • Enrollment change • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression • ALK mutation
|
cisplatin • carboplatin • Tyvyt (sintilimab)
13d
Multifocal papillary thyroid carcinoma with RET p.V804M, EML4-ALK fusion, and BRAF V600E positivity. (PubMed, JCEM Case Rep)
Histopathology confirmed multifocal PTC and a background of chronic lymphocytic thyroiditis with 23 lymph nodes negative for metastasis. This case presents heterogeneity of oncogenic drivers in PTC and the potential value of comprehensive molecular profiling in risk stratification and management.
Journal
|
BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • EML4 (EMAP Like 4)
|
BRAF V600E • BRAF V600 • ALK fusion • ALK mutation • RET mutation • RET V804*
17d
An open-label, dose-escalation and dose-expansion clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of combination therapy with LAT010 plus pembrolizumab in patients with locally advanced or metastatic solid tumors (ChiCTR2600121542)
P=N/A, N=27, Shanxi Bethune Hospital; Shanxi Bethune Hospital
New trial
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK mutation
|
Keytruda (pembrolizumab)
17d
A prospective, single-arm clinical study of QL1706 monotherapy in elderly patients with driver gene-negative, PD-L1-positive NSCLC (ChiCTR2600121140)
P=N/A, N=40, The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University
New trial
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression • BRAF V600E • EGFR mutation • BRAF V600 • ALK mutation
|
PD-L1 IHC 22C3 pharmDx
|
Qibeian (iparomlimab/tuvonralimab)
17d
HS-20093-309: A Multicenter, Randomized, Open-Label, Controlled Phase III Clinical Study Evaluating the Efficacy and Safety of HS-20093 Injection Combined with Adebrelimab versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer without Actionable Genomic Alterations (ChiCTR2600121048)
P3, N=450, Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital
New P3 trial
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD276 (CD276 Molecule)
|
PD-L1 expression • EGFR mutation • ALK fusion • ALK mutation • ROS1 fusion
|
docetaxel • AiRuiLi (adebrelimab) • risvutatug rezetecan (GSK5764227)
17d
Deep Learning-Based Multicenter Study on Intelligent Diagnosis and Treatment Response Assessment of Solid Tumors (ChiCTR2600120951)
P=N/A, N=500, Recruiting, Wuxi people’s Hospital; Wuxi people’s Hospital
New trial
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
PD-L1 expression • EGFR mutation • ALK mutation
17d
A prospective, randomized, double-arm, multi-center, phase II study to Investigate the Efficacy and Safety of Sintilimab in Combination with IpilimumabN01 and Chemotherapy in First-line Treatment of driver gene-negative advanced NSCLC with PDL1 TPS<1% (ChiCTR2600119741)
P2, N=80, PLA General Hospital; PLA General Hospital
New P2 trial
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • HER-2 mutation • ALK mutation • ROS1 fusion • MET mutation
|
PD-L1 IHC 22C3 pharmDx
|
Yervoy (ipilimumab) • Tyvyt (sintilimab) • pemetrexed
17d
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer (ChiCTR2600118958)
P2, N=130, Shandong First Medical University Affiliated Tumor Hospital; Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Canc
New P2 trial
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK mutation
|
Imfinzi (durvalumab) • Hensify (crystalline hafnium oxide)
17d
Construction of an Artificial Intelligence System for Predicting the Efficacy of Lung Cancer Immunotherapy and Early Warning of Immune-Related Adverse Reactions Based on Multi-Modal Data (ChiCTR2600118816)
P=N/A, N=5000, The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University
New trial
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation • ALK mutation
Share via
